NEW YORK (GenomeWeb News) – BGI and Novo Nordisk today announced a collaboration to create a "global collaboration framework."
The two firms provided few details about the agreement but said that it would create an opportunity for them to "accelerate their growth, execute their global partnering strategy and support disease research and development efforts." BGI will contribute its next-generation sequencing platforms and bioinformatics capabilities, and Novo Nordisk will contribute its drug development expertise.
Financial and other terms were not disclosed.
Last month BGI officially opened its European Genome Research Center in Denmark, where Novo Nordisk is heaquartered, and in a statement today Ning Li, director of BGI Europe, said it would provide "an excellent platform for us and our collaborators."